1. An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia
- Author
-
B. Ya. Alekseev, K. M. Nyushko, R. A. Gafanov, A. A. Kirichek, Yu. V. Anzhiganova, E. I. Kopyltsov, Yu. Yu. Sundui, and V. B. Matveev
- Subjects
medicine.medical_specialty ,non-metastatic castration-resistant prostate cancer ,genetic structures ,Urology ,Context (language use) ,androgen deprivation therapy ,new generation antiandrogen ,Androgen deprivation therapy ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,Epidemiology ,medicine ,Enzalutamide ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Stage (cooking) ,business.industry ,Apalutamide ,prostate-specific antigen doubling time ,medicine.disease ,Prostate-specific antigen ,Oncology ,chemistry ,Nephrology ,030220 oncology & carcinogenesis ,Medicine ,Surgery ,business - Abstract
Objective: to study the clinical and demographic profile of patients with non-metatstatic castration-resistant prostate cancer (nmCRPC) and clinical approaches to the treatment of nmCRPC in the context of daily medical practice before and after progression M1 stage.Materials and methods. The multicenter non-interventional epidemiological study is planned to include 200 patients with a documented diagnosis of nmCRPC from 2019 to 2020. The interim report has included data on 108 patients from 13 centers located in different regions of the Russian Federation. The median age of the patients was 73 (55—90) years.Results and conclusion. When the diagnosis of nmCRPC was made, the median prostate specific antigen was 8.23 (0.17—116.9) ng/ml, and the prostate specific antigen doubling time was 6 (1—50) months. When diagnosed nmCRPC, 86 patients (79.6 %) underwent a change of therapy, of which 42 % were prescribed modern regimens containing the new generation non-steroid antiandrogens (apalutamide, enzalutamide).
- Published
- 2020